Berry Genomics

What Berry Genomics does

Berry Genomics is a Beijing-based, publicly traded (szse:000710) clinical genomics company founded in 2010, operating with 1,001–5,000 employees and headquartered in China. The company's core business is developing and commercializing genetic testing products for clinical and public health applications in China, with a portfolio that includes non-invasive prenatal testing (NIPT), carrier screening, and — as of November 2025 — clinical-grade long-read sequencing via the PacBio Sequel II CNDx system and a thalassemia assay approved by China's NMPA. The underlying technology is single-molecule real-time (SMRT) sequencing, supplied through a technology partnership with Pacific Biosciences (PacBio), which Berry Genomics leverages to pursue high-accuracy comprehensive genomic analysis for complex genetic disorders such as thalassemia. The Sequel II CNDx approval represents the first clinical-grade long-read sequencer approval in China, giving Berry Genomics a regulatory first-mover position in this clinical category.

Name

Berry Genomics

Legal name

Berry Genomics

Website

https://berrygenomics.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Berry Genomics is a Beijing-based, publicly traded Chinese clinical genomics company that develops NIPT, carrier screening, and clinical-grade long-read sequencing products — including the NMPA-approved PacBio Sequel II CNDx system and thalassemia assay — serving healthcare providers and public health screening programs in China.

Ownership category

akta.pro rank

Product category

Clinical Genomics and Genetic Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Clinical genomic sequencing
• Long-read DNA sequencing
• Non-invasive prenatal testing
• Carrier screening diagnostics
• Genetic disease diagnostics

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Core offering

Berry Genomics develops and commercializes clinical genomic testing products and services, including non-invasive prenatal testing (NIPT), carrier screening, and clinical diagnostics for genetic disorders. Its portfolio includes the PacBio Sequel II CNDx long-read sequencer (the first NMPA-approved clinical-grade long-read sequencer in China) and diagnostic assays such as the thalassemia assay, all powered by single-molecule real-time (SMRT) sequencing technology.

Product overview

Berry Genomics is a genetic testing company specializing in non-invasive prenatal testing (NIPT), carrier screening, and clinical genomic diagnostics. The company's portfolio centers on the PacBio Sequel II CNDx system (a long-read sequencing platform) and associated diagnostic assays including a thalassemia assay, all powered by single-molecule real-time (SMRT) sequencing technology. Berry Genomics operates as a subsidiary unit with focus on next-generation gene sequencing for clinical applications in China, having achieved the first regulatory approval for clinical-grade long-read sequencing in the country.

Differentiator

Problem solved

Functional benefit

Products and services

• Sequel II CNDx System A clinical-grade long-read sequencer developed by Pacific Biosciences in partnership with Berry Genomics. It is the first NMPA-approved clinical-grade long-read sequencer in China, enabling high-accuracy comprehensive genomic testing for genetic disorders such as thalassemia.
• Thalassemia Assay A diagnostic assay approved alongside the Sequel II CNDx system for detecting thalassemia and other genetic disorders. The assay utilizes single-molecule real-time (SMRT) sequencing technology to improve diagnosis of genetic diseases.
• Non-Invasive Prenatal Testing (NIPT) Non-invasive prenatal testing services offered by Berry Genomics as part of its clinical genomics portfolio, used by expectant mothers and their obstetricians to detect fetal chromosomal abnormalities during pregnancy.
• Carrier Screening Clinical genetic carrier screening services offered by Berry Genomics, allowing prospective parents to assess their risk of passing inherited genetic conditions to their children.
• Clinical Genomic Diagnostics Clinical-grade genomic diagnostic services for genetic disorders leveraging Berry Genomics' long-read sequencing platform and diagnostic assays, offered through Chinese hospitals and clinical laboratories.

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Pacific Biosciences (PacBio)coreTechnology or Integration · 4 November 2025Berry Genomics partnered with PacBio to achieve regulatory approval for the Sequel II CNDx system from China's NMPA. This marked the first regulatory clearance of a clinical-grade long-read sequencer in China. The partnership enables Berry Genomics to offer PacBio's HiFi sequencing technology for complex genetic testing, particularly for diseases like thalassemia. The approval allows Chinese clinicians to perform high-accuracy comprehensive genomic analysis in clinical settings.

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• BGI Genomics: BGI is China's largest genomics and clinical sequencing services provider, offering NIPT, rare-disease panels, and population genomics. It is the dominant incumbent competing against Berry Genomics across prenatal screening and clinical sequencing in China.
• KingMed Diagnostics: KingMed is a leading independent clinical laboratory chain in China providing specialty genetic, pathology, and molecular diagnostic services. It is a broad incumbent across clinical testing including the segments Berry Genomics targets.

Direct peers

• Annoroad Genomics: Annoroad is a Chinese NGS-based clinical diagnostics company with NIPT, reproductive health, and tumor testing offerings. It competes directly with Berry Genomics in China's prenatal and clinical sequencing market.
• Da An Gene (Kingstar): Da An Gene operates one of China's largest clinical diagnostic laboratory networks with broad molecular and genetic testing menus, including prenatal and infectious disease testing — direct overlap with Berry Genomics' clinical services.
• Natera: Natera is a US-listed reproductive and oncology genetics testing company with leading NIPT and carrier screening franchises. It is the most direct international comparability point for Berry Genomics' prenatal and carrier screening business model.
• Myriad Genetics: Myriad is an established US genetic testing company with carrier screening, prenatal, and hereditary cancer tests. It serves as a direct business-model peer for clinical germline genetic testing services.
• NeoGenomics: NeoGenomics operates clinical genetic and oncology testing labs serving hospitals and physicians in the US and internationally. It is comparable to Berry Genomics as a clinical genomics services provider serving healthcare providers.

Others

• Pacific Biosciences (PacBio): PacBio is the developer of SMRT/HiFi long-read sequencing and the technology partner behind Berry Genomics' Sequel II CNDx system. While not a commercial competitor, PacBio is materially comparable because it sets the technology roadmap Berry Genomics' clinical long-read franchise depends on.

Emerging players

• QIAGEN: QIAGEN supplies molecular diagnostic sample technologies, PCR/NGS reagents, and bioinformatics used in clinical genetic testing labs. It is an emerging player in the same sample-to-result workflows Berry Genomics' clinical sequencing business relies upon.
• Oxford Nanopore Technologies: Oxford Nanopore develops long-read nanopore sequencing platforms used in clinical and research genomics. It is comparable to Berry Genomics' PacBio-based long-read offering as a competing long-read technology approach entering clinical use globally.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Berry Genomics